Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Abstract: Information Extraction (IE) and Text Classification (CLS) serve as the fundamental pillars of NLU, with both disciplines relying on analyzing input sequences to categorize outputs into ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

A Samsung AI researcher in Montreal has created a tiny AI model that punches far above its weight, challenging the industry’s focus on massive scale. Released this week, the 7-million-parameter Tiny ...

School of Physics and Optoelectronics, Xiangtan University, Xiangtan, Hunan, China Accurate reconstruction of optical fiber curves has important applications in fields like medicine, aerospace, and ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

Touching Base is the dynamic podcast series from the editors of GEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, ...